Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin 2021;71(3):264-279. https://doi.org/10.3322/caac.21657

Article  PubMed  Google Scholar 

Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, Wu J, Liu B, Ying X, Liu Y. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut 2021;70(3):464-475. https://doi.org/10.1136/gutjnl-2019-320368

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40. https://doi.org/10.1016/S0140-6736(21)00797-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res 2020;26(4):846-854. https://doi.org/10.1158/1078-0432.CCR-19-2443

Article  CAS  PubMed  Google Scholar 

Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol 2021;18(8):473-487. https://doi.org/10.1038/s41571-021-00492-2

Article  PubMed  Google Scholar 

Porcu M, Solinas C, Mannelli L, Micheletti G, Lambertini M, Willard-Gallo K, Neri E, Flanders AE, Saba L. Radiomics and “radi-...omics” in cancer immunotherapy: a guide for clinicians. Crit Rev Oncol Hematol 2020;154:103068. https://doi.org/10.1016/j.critrevonc.2020.103068

Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Nunez NG, De Feo D, Kickingereder P, Fischer M, Green E, Sadik A, Friedrich M, Sanghvi K, Kilian M, Cichon F, Wolf L, Jahne K, von Landenberg A, Bunse L, Sahm F, Schrimpf D, Meyer J, Alexander A, Brugnara G, Roth R, Pfleiderer K, Niesler B, von Deimling A, Opitz C, Breckwoldt MO, Heiland S, Bendszus M, Wick W, Becher B, Platten M. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun 2020;11(1):931. https://doi.org/10.1038/s41467-020-14642-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wen Q, Yang Z, Dai H, Feng A, Li Q. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. Front Oncol 2021;11:620246. https://doi.org/10.3389/fonc.2021.620246

Article  PubMed  PubMed Central  Google Scholar 

Sun Z, Hu S, Ge Y, Wang J, Duan S, Song J, Hu C, Li Y. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features. J Xray Sci Technol 2020;28(3):449-459. https://doi.org/10.3233/XST-200642

Article  CAS  PubMed  Google Scholar 

Park KJ, Lee JL, Yoon SK, Heo C, Park BW, Kim JK. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma. Eur Radiol 2020;30(10):5392-5403. https://doi.org/10.1007/s00330-020-06847-0

Article  CAS  PubMed  Google Scholar 

Yaqub M, Javaid MK, Cooper C, Noble JA. Investigation of the role of feature selection and weighted voting in random forests for 3-D volumetric segmentation. IEEE Trans Med Imaging 2014;33(2):258-271. https://doi.org/10.1109/TMI.2013.2284025

Article  CAS  PubMed  Google Scholar 

Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004;27(5):599-605. https://doi.org/10.1248/bpb.27.599

Article  CAS  PubMed  Google Scholar 

Chang X, Guo X, Li X, Han X, Li X, Liu X, Ren J. Potential Value of Radiomics in the Identification of Stage T3 and T4a Esophagogastric Junction Adenocarcinoma Based on Contrast-Enhanced CT Images. Front Oncol 2021;11:627947. https://doi.org/10.3389/fonc.2021.627947

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Liu W, Yu Y, Liu JJ, Xue HD, Qi YF, Lei J, Yu JC, Jin ZY. CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer. Eur Radiol 2020;30(2):976-986. https://doi.org/10.1007/s00330-019-06398-z

Article  PubMed  Google Scholar 

Yang J, Wu Q, Xu L, Wang Z, Su K, Liu R, Yen EA, Liu S, Qin J, Rong Y, Lu Y, Niu T. Integrating tumor and nodal radiomics to predict lymph node metastasis in gastric cancer. Radiother Oncol 2020;150:89-96. https://doi.org/10.1016/j.radonc.2020.06.004

Article  PubMed  Google Scholar 

Huang J, Chen Y, Zhang Y, Xie J, Liang Y, Yuan W, Zhou T, Gao R, Wen R, Xia Y, Long L. Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer. Abdom Radiol (NY) 2022;47(1):66-75. https://doi.org/10.1007/s00261-021-03287-2

Article  CAS  Google Scholar 

Liu S, He J, Liu S, Ji C, Guan W, Chen L, Guan Y, Yang X, Zhou Z. Radiomics analysis using contrast-enhanced CT for preoperative prediction of occult peritoneal metastasis in advanced gastric cancer. Eur Radiol 2020;30(1):239-246. https://doi.org/10.1007/s00330-019-06368-5

Article  PubMed  Google Scholar 

Xu Q, Sun Z, Li X, Ye C, Zhou C, Zhang L, Lu G. Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy. Eur Radiol 2021;31(11):8765-8774. https://doi.org/10.1007/s00330-021-07962-2

Article  PubMed  PubMed Central  Google Scholar 

Wang W, Peng Y, Feng X, Zhao Y, Seeruttun SR, Zhang J, Cheng Z, Li Y, Liu Z, Zhou Z. Development and Validation of a Computed Tomography-Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. JAMA Netw Open 2021;4(8):e2121143. https://doi.org/10.1001/jamanetworkopen.2021.21143

Article  PubMed  PubMed Central  Google Scholar 

Wang XX, Ding Y, Wang SW, Dong D, Li HL, Chen J, Hu H, Lu C, Tian J, Shan XH. Intratumoral and peritumoral radiomics analysis for preoperative Lauren classification in gastric cancer. Cancer Imaging 2020;20(1):83. https://doi.org/10.1186/s40644-020-00358-3

Article  PubMed  PubMed Central  Google Scholar 

Huang J, Yao H, Li Y, Dong M, Han C, He L, Huang X, Xia T, Yi Z, Wang H, Zhang Y, He J, Liang C, Liu Z. Development and validation of a CT-based radiomics nomogram for preoperative prediction of tumor histologic grade in gastric adenocarcinoma. Chin J Cancer Res 2021;33(1):69-78. https://doi.org/10.21147/j.issn.1000-9604.2021.01.08

Article  PubMed  PubMed Central  Google Scholar 

Hao D, Li Q, Feng QX, Qi L, Liu XS, Arefan D, Zhang YD, Wu S. Identifying Prognostic Markers From Clinical, Radiomics, and Deep Learning Imaging Features for Gastric Cancer Survival Prediction. Front Oncol 2021;11:725889. https://doi.org/10.3389/fonc.2021.725889

Article  PubMed  Google Scholar 

Wang Y, Yu Y, Han W, Zhang YJ, Jiang L, Xue HD, Lei J, Jin ZY, Yu JC. CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer. Acad Radiol 2021;28(3):e86-e92. https://doi.org/10.1016/j.acra.2020.02.018

Article  PubMed  Google Scholar 

Wen Q, Yang Z, Zhu J, Qiu Q, Dai H, Feng A, Xing L. Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC. Onco Targets Ther 2020;13:12003-12013. https://doi.org/10.2147/OTT.S261068

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Ozguroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol 2021;7(6):895-902. https://doi.org/10.1001/jamaoncol.2021.0275

Article  PubMed  PubMed Central  Google Scholar 

Shur JD, Doran SJ, Kumar S, Ap Dafydd D, Downey K, O'Connor JPB, Papanikolaou N, Messiou C, Koh DM, Orton MR. Radiomics in Oncology: A Practical Guide. Radiographics 2021;41(6):1717-1732. https://doi.org/10.1148/rg.2021210037

Article  PubMed  Google Scholar